Advertisement

Topics

Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 Pipeline Review, H2 2017 [Report Updated: 08082017] Prices from USD $3500

08:52 EDT 17 Aug 2017 | BioPortfolio Reports

Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 Pipeline Review, H2 2017

Summary

Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 Tumor Necrosis Factor Receptor Superfamily Member 4 or OX40 is a member of the TNFreceptor superfamily. This receptor has been shown to activate NFkappaB through its interaction with adaptor proteins TRAF2 and TRAF5. OX40L binds to OX40 receptors on Tcells, preventing them from dying and subsequently increasing cytokine production. OX40 has a critical role in the maintenance of an immune response. OX40 also plays a crucial role in both Th1 and Th2 mediated reactions.

Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 pipeline Target constitutes close to 17 molecules. Out of which approximately 17 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 3, 5 and 4 respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal and Metabolic Disorders which include indications Solid Tumor, Head And Neck Cancer Squamous Cell Carcinoma, NonSmall Cell Lung Cancer, Bladder Cancer, Melanoma, Renal Cell Carcinoma, Atopic Dermatitis, Breast Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Graft Versus Host Disease GVHD, Hematological Tumor, Metastatic Cancer, Metastatic Hepatocellular Carcinoma HCC, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Soft Tissue Sarcoma, Systemic Lupus Erythematosus, Transplant Rejection, Type 1 Diabetes Juvenile Diabetes and Ulcerative Colitis.

The latest report Tumor Necrosis Factor Receptor Superfamily Member 4 Pipeline Review, H2 2017, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4
The report reviews Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 targeted therapeutics and enlists all their major and minor projects
The report assesses Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 Pipeline Review, H2 2017 [Report Updated: 08082017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 Pipeline Review, H2 2017 [Report Updated: 08082017] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cytokine Tumour Necrosis Factor (TNF)
TNF is a compound that is classified as a cytokine which plays a central role in the cellular mechanisms of apoptosis or cell death. However, there are a number of different kinds of TNF, just under twenty, but the family of molecules have very similar a...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...